Atezolizumab (anti-PD-L1)

目录号：A2004         批次号: A200411

打印

Atezolizumab (anti-PD-L1)是人源、IgG1单克隆抗体，阻止PD-L1与PD-1和B7.1的相互作用，但不影响PD-L2与PD-1的相互作用；MW：145 KD。

抗体信息

CAS号 1380723-44-3
配制 100 mM Pro-Ac, 20mM Arg, pH5.0
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 7.249mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Atezolizumab (anti-PD-L1)在文献中得到引用

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy [ Nat Commun, 2025, 16(1):4128] PubMed: 40319089
In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients [ Cell Death Dis, 2025, 16(1):286] PubMed: 40221409
Using extension-based mRNA display to design antibody-like proteinogenic peptides for human PD-L1 [ Protein Sci, 2025, 34(9):e70268] PubMed: 40852896
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) [ J Transl Med, 2025, 23(1):2] PubMed: 39748404
NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):132] PubMed: 40029463
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):143] PubMed: 40056167
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer [ iScience, 2025, 28(3):111943] PubMed: 40034862
Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 [ Respir Res, 2025, 26(1):17] PubMed: 39815269

禁止用于人体及治疗！